These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 1163425)

  • 21. Intravenous quinidine: relations among concentration, tachyarrhythmia suppression and electrophysiologic actions with inducible sustained ventricular tachycardia.
    Duff HJ; Wyse DG; Manyari D; Mitchell LB
    Am J Cardiol; 1985 Jan; 55(1):92-7. PubMed ID: 3966404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of oral quinidine on intraventricular conduction in man: correlation of plasma quinidine with changes in QRS duration.
    Heissenbuttel RH; Bigger JT
    Am Heart J; 1970 Oct; 80(4):453-62. PubMed ID: 5471206
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomized, double-blind, parallel group comparison of disopyramide phosphate and quinidine in patients with cardiac arrhythmias.
    Arif M; Laidlaw JC; Oshrain C; Willis PW; Nissen CH; McDermott DJ; Smith WS; Karim A; Wilson RR
    Angiology; 1983 Jun; 34(6):393-400. PubMed ID: 6408949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects.
    Vozeh S; Uematsu T; Guentert TW; Ha HR; Follath F
    Clin Pharmacol Ther; 1985 May; 37(5):575-81. PubMed ID: 3987181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quinidine: an update on therapeutics, pharmacokinetics and serum concentration monitoring.
    Crevasse L
    Am J Cardiol; 1988 Nov; 62(14):22I-23I. PubMed ID: 3189164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.
    Jaillon P; Poirier JM; Lecocq B; Jarreau C; Pays M; Richard MO; Cheymol G
    Eur J Drug Metab Pharmacokinet; 1986; 11(3):233-8. PubMed ID: 3816879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinidine therapy in hospitalized patients with ventricular arrhythmias.
    Carliner NH; Crouthamel WG; Fisher ML; Mugmon MA; Vassar DL; Narang PK; Plotnick GD
    Am Heart J; 1979 Dec; 98(6):708-15. PubMed ID: 495420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute oral testing for determining antiarrhythmic drug efficacy. I. Quinidine.
    Gaughan CE; Lown B; Lanigan J; Voukydis P; Besser HW
    Am J Cardiol; 1976 Nov; 38(6):677-84. PubMed ID: 998504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quinidine saliva concentrations: absence of correlation with serum concentrations at steady state.
    Narang PK; Carliner NH; Fisher ML; Crouthamel WG
    Clin Pharmacol Ther; 1983 Nov; 34(5):695-702. PubMed ID: 6627830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacology and clinical biopharmacy of quinidine].
    Huynh-Ngoc T; Sirois G
    J Pharm Belg; 1974 Mar; 29(2):152-80. PubMed ID: 4840388
    [No Abstract]   [Full Text] [Related]  

  • 31. Steady-state serum quinidine concentration: role in prophylactic therapy following acute myocardial infarction.
    Halkin H; Vered Z; Millman P; Rabinowitz B; Neufeld HN
    Isr J Med Sci; 1979 Jul; 15(7):583-7. PubMed ID: 478822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tocainide kinetics in congestive heart failure.
    Mohiuddin SM; Esterbrooks D; Hilleman DE; Aronow WS; Patterson AJ; Sketch MH; Mooss AN; Hee TT; Reich JW
    Clin Pharmacol Ther; 1983 Nov; 34(5):596-603. PubMed ID: 6414753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quinidine concentration in blood and excretion in urine following parenteral administration as related to congestive heart failure.
    DITLEFSEN EM
    Acta Med Scand; 1957 Nov; 159(2):105-9. PubMed ID: 13497617
    [No Abstract]   [Full Text] [Related]  

  • 34. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short- and long-acting oral quinidine preparations: clinical implications of pharmacokinetic differences.
    Woo E; Greenblatt DJ; Ochs HR
    Angiology; 1978 Mar; 29(3):243-50. PubMed ID: 646185
    [No Abstract]   [Full Text] [Related]  

  • 36. Digoxin-quinidine interaction Pharmacokinetic evaluation.
    Hager WD; Fenster P; Mayersohn M; Perrier D; Graves P; Marcus FI; Goldman S
    N Engl J Med; 1979 May; 300(22):1238-41. PubMed ID: 431681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacology and pharmacokinetics of pirmenol.
    Reiter MJ
    Angiology; 1988 Mar; 39(3 Pt 2):293-8. PubMed ID: 3281518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.
    Frigo GM; Perucca E; Teggia-Droghi M; Gatti G; Mussini A; Salerno J
    Br J Clin Pharmacol; 1977 Aug; 4(4):449-54. PubMed ID: 901736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interaction of cimetidine with quinidine, procainamide and digoxin].
    Halawa B; Mazurek W
    Pol Tyg Lek; 1985 Dec 23-30; 40(51-52):1437-9. PubMed ID: 3831993
    [No Abstract]   [Full Text] [Related]  

  • 40. Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol.
    Kessler KM; Humphries WC; Black M; Spann JF
    Am Heart J; 1978 Nov; 96(5):627-35. PubMed ID: 263396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.